Free Trial

NuCana (NCNA) Stock Price, News & Analysis

+0.11 (+3.13%)
(As of 11:02 AM ET)
Today's Range
50-Day Range
52-Week Range
5,679 shs
Average Volume
52,943 shs
Market Capitalization
$9.59 million
P/E Ratio
Dividend Yield
Price Target

NuCana MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
3,343.5% Upside
$125.00 Price Target
Short Interest
1.21% of Float Sold Short
Dividend Strength
News Sentiment
1.58mentions of NuCana in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($8.35) to ($10.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

NCNA stock logo

About NuCana Stock (NASDAQ:NCNA)

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NCNA Stock Price History

NCNA Stock News Headlines

NuCana plc (NCNA)
NuCana Announces Completion of ADS Ratio Change
NuCana Announces Plan to Implement ADS Ratio Change
Nucana (NCNA) Receives a Hold from TD Cowen
NuCana: Q4 Earnings Insights
Why NuCana Stock Is Up Today
Why Is NuCana (NCNA) Stock Up 102% Today?
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.86 per share


Free Float
Market Cap
$9.33 million
Not Optionable
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Hugh Stephen Griffith (Age 56)
    Founder, CEO & Executive Director
    Comp: $1.21M
  • Mr. Donald Munoz (Age 55)
    Chief Financial Officer
  • Mr. David Harrison (Age 64)
    Head of Translational Medicine
  • Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)
    M.D., Chief Medical Officer
  • Ms. Theresa Bruce
    Senior Vice President of Clinical Operations
  • Ms. Elisabeth Oelmann
    Senior Vice President of Medical & Clinical Development
  • Martin Quinn
    Company Secretary

NCNA Stock Analysis - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings
or view top-rated stocks.

What is NuCana's stock price target for 2024?

2 brokerages have issued twelve-month price objectives for NuCana's shares. Their NCNA share price targets range from $100.00 to $150.00. On average, they predict the company's stock price to reach $125.00 in the next year. This suggests a possible upside of 3,343.5% from the stock's current price.
View analysts price targets for NCNA
or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2024?

NuCana's stock was trading at $7.3950 at the beginning of the year. Since then, NCNA shares have decreased by 50.9% and is now trading at $3.63.
View the best growth stocks for 2024 here

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our NCNA earnings forecast

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) posted its quarterly earnings results on Wednesday, March, 20th. The company reported ($4.25) earnings per share for the quarter, missing analysts' consensus estimates of ($3.25) by $1.00.

When did NuCana's stock split?

NuCana's stock reverse split on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of NuCana own?
When did NuCana IPO?

NuCana (NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NCNA) was last updated on 5/24/2024 by Staff

From Our Partners